Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, and Preliminary Antileukemic Activity of GDX012 in Patients With Minimal Residual Disease (MRD) Positive Acute Myeloid Leukemia

Next Previous
X
Search
Trial Profile

A Phase 1, Open Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, and Preliminary Antileukemic Activity of GDX012 in Patients With Minimal Residual Disease (MRD) Positive Acute Myeloid Leukemia

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 22 Jul 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TAK 012 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; First in man
  • Sponsors GammaDelta Therapeutics

    • Most Recent Events

    • 18 Jul 2022 Status changed from recruiting to discontinued.
    • 13 Apr 2022 Trial design presented at the 113th Annual Meeting of the American Association for Cancer Research.
    • 15 Sep 2021 According to a GammaDelta Therapeutics media release, First dose delivered to patients of this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top